<DOC>
	<DOCNO>NCT00175253</DOCNO>
	<brief_summary>Our experience suggest research alemtuzumab attractive islet transplantation . Therefore , study propose combine alemtuzumab induction pre-transplant , tacrolimus mycophenolate mofetil maintenance immunosuppression post-transplant . In critical early phase post transplant , anticipate regimen prove effective control autoimmunity rejection event , desirable side-effect profile , previously test combination induction immunosuppressive agent .</brief_summary>
	<brief_title>Alemtuzumab Induction Islet Transplantation</brief_title>
	<detailed_description>This trial single-center , prospective , open-label study 12 Type 1 diabetic participant receive islet-alone transplant along alemtuzumab induction therapy follow combination tacrolimus MMF maintenance immunosuppression . Participants receive 1 3 infusion pancreatic islet sufficient quantity attain insulin independence . The primary objective protocol ass safety treatment regimen utilize alemtuzumab induction combination tacrolimus MMF maintenance immunosuppression adult Type 1 diabetic participant receive first islet transplant .</detailed_description>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>open Canadians participant must Type 1 diabetes mellitus 5 year diabetes must complicate least 1 follow situation persist despite intensive insulin management effort : ( 1 ) Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 3.0 mmol/L , indicate , 2 episode severe hypoglycemia require third party assistance within 12 month ; ( 2 ) Metabolic instability , characterize erratic blood glucose level interfere daily activity 2 hospital visit diabetic ketoacidosis last 12 month . Participants must capable understand purpose risk study must sign statement informed consent . Severe coexist cardiac disease Active alcohol substance abuse , include cigarette smoke Psychiatric disorder make subject suitable candidate transplantation History nonadherence prescribe regimen Active infection include Hepatitis C , Hepatitis B , HIV , TB Any history current malignancy except squamous basal skin cancer BMI &gt; 28 kg/m2 screen visit Creatinine clearance &lt; 65 mL/min/1.73 m2 Blood creatinine &gt; 150 Âµmol/L ( 1.7 mg/dL ) Macroalbuminuria ( urinary albumin excretion rate &gt; 300 mg/24h ) Baseline Hb &lt; 105g/L ( &lt; 10.5 g/dL ) woman , &lt; 130 g/L ( &lt; 13 g/dL ) men Baseline screen liver function test outside normal range Untreated proliferative retinopathy Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breast feed Previous transplant , evidence significant sensitization PRA Insulin requirement &gt; 1.0 U/kg/day HbA1C &gt; 12 % Uncontrolled hyperlipidemia Under treatment medical condition require chronic use steroid Use coumadin anticoagulant therapy ( except aspirin ) subject PT INR &gt; 1.5 Untreated Celiac disease Patients Graves disease exclude unless previously adequately treated radioiodine ablative therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>islet</keyword>
	<keyword>transplantation</keyword>
</DOC>